SCHEMBL13675738

SCHEMBL13675738

CC(C)(C)c1ccc(/C=C/C(=O)Nc2ccc3cccnc3c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 14/20 1.00
RAB9A P51151 3/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
NPC1 O15118 2/20 0.63
LMNA P02545 2/20 0.63
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
MAPT P10636 3/20 0.60
MAPK1 P28482 2/20 0.60
KDM4E B2RXH2 1/20 0.60
POLB P06746 1/20 0.60
HPGD P15428 1/20 0.60
TSHR P16473 1/20 0.55
MTOR P42345 1/20 0.55
IMPDH2 P12268 1/20 0.54
MCHR1 Q99705 1/20 0.54
TP53 P04637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13675647 0.91 TRPV1 (0.84) TRPV1RAB9ASMN1; SMN2NPC1LMNA
SCHEMBL13675624 0.89 TRPV1 (0.80) TRPV1MCHR1
SCHEMBL3998577 0.86 TRPV1 (0.76) TRPV1RAB9ASMN1; SMN2NPC1LMNA
SCHEMBL3998585 0.86 TRPV1 (0.76) TRPV1RAB9ASMN1; SMN2NPC1LMNA
SCHEMBL13675838 0.86 TRPV1 (0.76) TRPV1RAB9ASMN1; SMN2NPC1LMNA
SCHEMBL13675625 0.85 TRPV1 (0.74) TRPV1RAB9ALMNAMEN1KMT2A
SCHEMBL13675660 0.83 TRPV1 (0.71) TRPV1RAB9ASMN1; SMN2NPC1LMNA
SCHEMBL4427327 0.81 MEN1 (0.73) TRPV1RAB9ANPC1MEN1KMT2A
SCHEMBL13675896 0.80 TRPV1 (0.66) TRPV1
SCHEMBL846063 0.79 TRPV1 (0.67) TRPV1RAB9ASMN1; SMN2NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 TRPV1 1/4885RAB9A 1356/4885SMN1; SMN2 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.